What Is Stearyl Glycyrrhetinate? Technical Brief, Anti-Inflammatory Data, and Formulating Oil-Soluble Licorice Derivatives

스테아릴 글리시레티네이트 is the lipophilic ester derived from 18β-glycyrrhetinic acid and stearyl alcohol. While water-soluble licorice extracts like Dipotassium Glycyrrhizate dominate aqueous serums, they struggle to penetrate the hydrophobic stratum corneum. Esterifying glycyrrhetinic acid with a C18 fatty chain solves this limitation. The result is a lipid-compatible active ingredient designed for anhydrous systems, emulsions, and lipid-barrier repair formulas.

Chemical Profile and Molecular Structure

• INCI 명칭: 스테아릴 글리시레티네이트
• CAS Number: 13832-70-7
• EINECS/ELINCS Number: 419-580-5
• Molecular Formula: C48H82O4
• Molecular Weight: 723.16 g/mol
• Chemical Structure: 18β-glycyrrhetinic acid 30-stearyl ester

Natural 18β-glycyrrhetinic acid contains a carboxylic acid group at the C-30 position. Esterification at C-30 with octadecanol (stearyl alcohol) increases lipophilicity (Log P = 6.2). This change facilitates passage through intercellular epidermal lipids. Once inside the stratum corneum, endogenous esterases gradually cleave the ester bond, releasing free glycyrrhetinic acid for sustained biological activity.

Standard Certificate of Analysis (COA) Specifications

The following table outlines the industrial raw material quality control criteria for cosmetics manufacturing:

Solubility Profile & Solvent Compatibility

Unlike salt forms of glycyrrhizic acid, Stearyl Glycyrrhetinate is virtually insoluble in water (9 μg/L at 20 °C). It requires dissolved lipid carriers or warm organic solvents.

Biological Mechanisms & In-Vitro Performance Data

Stearyl Glycyrrhetinate modulates inflammatory cascades primarily by inhibiting 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and downstream arachidonic acid pathways.

1. Inhibition of Pro-Inflammatory Mediators

Inflammatory stressors (UV radiation, chemical irritants, surfactant disruption) activate phospholipase A2. This enzyme releases arachidonic acid, converting it to prostaglandin E2 (PGE2) via cyclooxygenase-2 (COX-2).

2. Antimicrobial Benchmarks (MIC Values)

Broad-spectrum antimicrobial activity helps stabilize acne-prone and compromised skin microflora. Standard broth microdilution testing yields the following Minimum Inhibitory Concentrations (MIC):

• Cutibacterium acnes (ATCC 6919): MIC = 62.5 μg/mL
• Staphylococcus aureus (ATCC 6538): MIC = 125 μg/mL
• Staphylococcus epidermidis (ATCC 12228): MIC = 250 μg/mL

3. In-Vivo Erythema Reduction Study

A randomized split-face clinical test measured erythema reduction following sodium lauryl sulfate (SLS, 2% patch) irritation. Twenty subjects applied a formulation containing 0.2% Stearyl Glycyrrhetinate versus a placebo vehicle twice daily.

Formulating with Stearyl Glycyrrhetinate

Why choose Stearyl Glycyrrhetinate over traditional licorice salts? High concentrations of ionic salts like Dipotassium Glycyrrhizate can destabilize emulsion systems or break polymeric thickeners (such as Carbomer or Acrylates/C10-30 Alkyl Acrylate Crosspolymer). Stearyl Glycyrrhetinate is non-ionic and lipophilic, making it completely neutral to emulsion viscosity.

Phase Processing and Heating Requirements

1. Add Stearyl Glycyrrhetinate directly to the polar or medium-polar oil phase (MCT, C12-15 Alkyl Benzoate, or Squalane).
2. Heat the oil phase to 75 °C – 80 °C under moderate stirring until the powder dissolves completely into a clear liquid.
3. Perform emulsification with the water phase at equal temperature.
4. If cooling down rapidly, ensure the oil phase has enough solubilizing esters to prevent re-crystallization below 45 °C.

Suggested Dosage Matrix

Synergistic Active Combinations

• Bisabolol (0.2%) + Stearyl Glycyrrhetinate (0.1%): Combined inhibition of both 5-LOX and COX-2 pathways.
• Ceramide NP (0.1%) + Stearyl Glycyrrhetinate (0.2%): Rebuilds intercellular lipids while reducing sub-clinical barrier inflammation.
• Tocopherol (0.5%) + Stearyl Glycyrrhetinate (0.1%): Protects lipophilic active ingredients from oxidation while preventing squalene peroxidation on skin.

Comparative Analysis: Stearyl Glycyrrhetinate vs. Dipotassium Glycyrrhizate

Regulatory Status and Safety Assessment

• US CIR (Cosmetic Ingredient Review): Assessed as safe for use in cosmetic formulations up to 1.0%.
• EU SCCS / CosIng: Listed without specific restriction (Ref No: 38334); standard cosmetic safety limits apply.
• China NMPA (IECIC): Included in the Inventory of Existing Cosmetic Ingredients in China.
• Japan (Quasi-Drug Active): Approved as an active ingredient for anti-inflammatory and soothing claims within specified limits (0.1% – 0.5%).

Phototoxicity and sensitization studies confirm that Stearyl Glycyrrhetinate exhibits zero phototoxic potential at 1.0% concentration. It passes standard Human Repeat Insult Patch Tests (HRIPT) with no observed irritation.

Packaging, Storage, and Handling

• 포장: Standard industrial supply comes in aluminum foil bags or fiber drums lined with double-layer polyethylene bags.
• 보관 조건: Keep containers tightly sealed in a cool, dry, and ventilated place (15 °C – 25 °C). Protect from direct sunlight and moisture.
• 유통기한: 24 months from manufacturing date when stored in unopened original containers.
• Sample Requests: Pure grade production samples are available for research and R&D formulation trials upon request.

Literature & Scientific References

1. Cosmetic Ingredient Review Expert Panel. (2007). Final Report on the Safety Assessment of Glycyrrhetinic Acid, its Salts, and Esters. International Journal of Toxicology, 26(Suppl 2), 79–112.
2. Shibata, S. (2000). A review of the anti-inflammatory actions of licorice and its active compounds. Journal of the Pharmaceutical Society of Japan, 120(10), 849–862.
3. Finney, R. S. H., & Somers, G. F. (1958). The anti-inflammatory activity of glycyrrhetinic acid and its derivatives. Journal of Pharmacy and Pharmacology, 10(1), 613–620.
4. Yokota, T., Nishio, H., Kubota, Y., & Mizoguchi, M. (1998). The inhibitory effect of licorice extract on melanogenesis and inflammation. Pigment Cell Research, 11(6), 355–361.
5. Inagaki, N., et al. (2006). Inhibitory effects of 18β-glycyrrhetinic acid derivatives on immediate and delayed-type hypersensitivity reactions. Biological and Pharmaceutical Bulletin, 29(8), 1734–1739.